Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA by Andrew Blauvelt, Alyssa Garrelts, William Malatestinic, Julie Birt, Baojin Zhu, Meghan Feely

Connect to this object online.

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History by Andrew Blauvelt, Howard Kallender, Daniel Sturm, Qian Li, Haobo Ren, Lawrence F. Eichenfield

Connect to this object online.

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies by Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield

Connect to this object online.

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial by Jonathan Weyne, Andrew Blauvelt, Marjolein de Bruin-Weller, Errol Prens, Penny Asbell, Debra Sierka, Zhen Chen, Brad Shumel

Connect to this object online.

Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry by Philip J. Mease, Andrew Blauvelt, Adam P. Sima, Silky W. Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark G. Lebwohl

Connect to this object online.

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis by April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt

Connect to this object online.

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt

Connect to this object online.

Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry by Andrew Blauvelt, Robert R. McLean, Silky W. Beaty, Adam P. Sima, Robert Low, Jeffrey L. Stark, Laura McClung, Jerry Bagel

Connect to this object online.

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review by Andrew Blauvelt, Richard G. Langley, Kenneth B. Gordon, Jonathan I. Silverberg, Kilian Eyerich, Morten O. A. Sommer, Jakob Felding, Richard B. Warren

Connect to this object online.

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-Wo... by April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt

Connect to this object online.

Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis by Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt

Connect to this object online.

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) by Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl

Connect to this object online.

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy by Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp

Connect to this object online.

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials by Kenneth B. Gordon, Andrew Blauvelt, Hervé Bachelez, Laura C. Coates, Filip E. Van den Bosch, Blair Kaplan, Willem Koetse, Doug G. Ashley, Ralph Lippe, Ranjeeta Sinvhal, Kim A. Papp

Connect to this object online.

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy by Andrew Blauvelt, Yanqing Chen, Patrick J. Branigan, Xuejun Liu, Samuel DePrimo, Brice E. Keyes, Monica Leung, Steven Fakharzadeh, Ya-Wen Yang, Ernesto J. Muñoz-Elías, James G. Krueger, Richard G. Langley

Connect to this object online.

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials by Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt

Connect to this object online.

Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 studyCapsule Summary by Neal Bhatia, MD, Edward Lain, MD, Abel Jarell, MD, Janet DuBois, MD, Maria Luisa Tamarit, MD, Meritxell Falques, MSc, Vera Kiyasova, MD, PhD, Laura Padullés, PhD, Raquel Otero, PhD, Andrew Blauvelt, MD, MBA

Connect to this object online.

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis by Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg

Connect to this object online.

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure by April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl

Connect to this object online.

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic De... by Eric L. Simpson, Marjolein de Bruin-Weller, H. Chih-ho Hong, Delphine Staumont-Sallé, Andrew Blauvelt, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, Zhuqing Liu, Helena Agell, Jonathan I. Silverberg

Connect to this object online.